dihydroxyphenylalanine has been researched along with Disease Exacerbation in 42 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The investigation of disease progression provides important information on the dynamics of cell death in Parkinson disease (PD)." | 5.33 | Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. ( Coburger, S; Ghaemi, M; Heiss, WD; Herholz, K; Hilker, R; Jacobs, AH; Rudolf, J; Schweitzer, K; Weisenbach, S, 2005) |
| "Braak's staging concept of Lewy body disease pathogenesis is based on a spatiotemporal sequence of alpha-synuclein deposition, with autonomic nervous system involvement before synucleinopathy in substantia nigra neurons." | 3.78 | Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. ( Goldstein, DS; Holmes, C; Park, MY; Sewell, L; Sharabi, Y, 2012) |
| "The ability of N-beta-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD)-a novel catechol derivative isolated from an insect as an antibacterial substance-to scavenge free radicals and prevent cataract progression was examined." | 3.75 | 5-S-GAD, a novel radical scavenging compound, prevents lens opacity development. ( Akiyama, N; Natori, S; Nishigori, H; Sogo, S; Tsujimoto, M; Umeda, IO, 2009) |
| "Transient exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome resembling idiopathic parkinsonism (IP)." | 3.69 | Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. ( Calne, DB; Langston, JW; Schulzer, M; Snow, BJ; Tetrud, JW; Vingerhoets, FJ, 1994) |
| "With respect to Parkinson's disease PET and later SPECT allowed the number of dopaminergic neurons to be assessed in vivo." | 2.46 | [Nuclear medicine imaging in patients with Parkinson's syndrome: an update]. ( Schwarz, J, 2010) |
| "A major goal of research in Parkinson's disease (PD) has been the development of treatments to slow the progressive degeneration of the nigrostriatal dopaminergic system and to reduce the functional decline of patients." | 2.42 | Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. ( Brooks, DJ; Frey, KA; Marek, KL; Oakes, D; Paty, D; Prentice, R; Shults, CW; Stoessl, AJ, 2003) |
| "The power of (18)F-FDOPA PET to predict disease progression was evaluated with the Kaplan-Meier and Cox regression methods." | 1.40 | (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. ( Allen-Auerbach, M; Chen, W; Czernin, J; DeSalles, AA; Lizarraga, KJ; Phelps, ME; Yong, WH, 2014) |
| "The investigation of disease progression provides important information on the dynamics of cell death in Parkinson disease (PD)." | 1.33 | Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. ( Coburger, S; Ghaemi, M; Heiss, WD; Herholz, K; Hilker, R; Jacobs, AH; Rudolf, J; Schweitzer, K; Weisenbach, S, 2005) |
| "Thirty-one drug-naive patients with Parkinson's disease (PD) underwent 6-[18F]fluoro-L-dopa (F-dopa) positron emission tomography (PET) scan at the time of the diagnosis (baseline) and 2 years later in order to investigate F-dopa uptake in striatal and extrastriatal regions during the first years of early PD." | 1.33 | Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. ( Aalto, S; Bergman, J; Brück, A; Nurmi, E; Rinne, JO; Vahlberg, T, 2006) |
| "These results indicate that disease progression in patients with parkin mutations is slower than that of IPD patients." | 1.31 | Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. ( Brooks, DJ; Khan, NL; Lees, AJ; Pavese, N; Piccini, P; Sweeney, MG; Wood, NW, 2002) |
| "Previous imaging studies in Parkinson's disease have focused mainly on the striatum, a region with very high dopaminergic activity." | 1.31 | Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. ( Bergman, J; Brück, A; Eskola, O; Kaasinen, V; Nurmi, E; Rinne, JO; Solin, O, 2001) |
| "Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone." | 1.31 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002) |
| "Thirty two patients with Parkinson's disease (mean age 58 (SD 13) years, mean duration 39 (SD 33) months) were assessed with [18F]dopa PET and UPDRS scoring on two occasions a mean of 18 (SD 6) months apart." | 1.30 | Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. ( Bailey, DL; Brooks, DJ; Morrish, PK; Rakshi, JS; Sawle, GV, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (14.29) | 18.2507 |
| 2000's | 20 (47.62) | 29.6817 |
| 2010's | 16 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Lao-Kaim, NP | 1 |
| Roussakis, AA | 1 |
| Martín-Bastida, A | 1 |
| Valle-Guzman, N | 1 |
| Paul, G | 1 |
| Loane, C | 1 |
| Widner, H | 1 |
| Politis, M | 1 |
| Foltynie, T | 1 |
| Barker, RA | 1 |
| Piccini, P | 3 |
| Veronese, M | 1 |
| Moro, L | 1 |
| Arcolin, M | 1 |
| Dipasquale, O | 1 |
| Rizzo, G | 1 |
| Expert, P | 1 |
| Khan, W | 1 |
| Fisher, PM | 1 |
| Svarer, C | 1 |
| Bertoldo, A | 1 |
| Howes, O | 1 |
| Turkheimer, FE | 1 |
| Lizarraga, KJ | 2 |
| Allen-Auerbach, M | 1 |
| Czernin, J | 1 |
| DeSalles, AA | 1 |
| Yong, WH | 1 |
| Phelps, ME | 1 |
| Chen, W | 2 |
| Morana, G | 2 |
| Piccardo, A | 2 |
| Milanaccio, C | 1 |
| Puntoni, M | 1 |
| Nozza, P | 2 |
| Cama, A | 1 |
| Zefiro, D | 1 |
| Cabria, M | 1 |
| Rossi, A | 2 |
| Garrè, ML | 2 |
| Li, CT | 1 |
| Palotti, M | 1 |
| Holden, JE | 2 |
| Oh, J | 1 |
| Okonkwo, O | 1 |
| Christian, BT | 1 |
| Bendlin, BB | 1 |
| Buyan-Dent, L | 1 |
| Harding, SJ | 1 |
| Stone, CK | 1 |
| DeJesus, OT | 1 |
| Nickles, RJ | 1 |
| Gallagher, CL | 1 |
| Guo, S | 1 |
| Lin, CM | 1 |
| Xu, Z | 1 |
| Miao, L | 1 |
| Wang, Y | 1 |
| Huang, L | 1 |
| De Salles, AA | 1 |
| Darcourt, J | 1 |
| Schiazza, A | 1 |
| Sapin, N | 1 |
| Dufour, M | 1 |
| Ouvrier, MJ | 1 |
| Benisvy, D | 1 |
| Fontana, X | 1 |
| Koulibaly, PM | 1 |
| Villani, V | 1 |
| Carapella, CM | 1 |
| Chiaravalloti, A | 1 |
| Terrenato, I | 1 |
| Piludu, F | 1 |
| Vidiri, A | 1 |
| Schillaci, O | 1 |
| Floris, R | 1 |
| Marzi, S | 1 |
| Fabi, A | 1 |
| Pace, A | 1 |
| Akiyama, N | 1 |
| Umeda, IO | 1 |
| Sogo, S | 1 |
| Nishigori, H | 1 |
| Tsujimoto, M | 1 |
| Natori, S | 1 |
| Nigmatullina, RR | 1 |
| Kirillova, VV | 1 |
| Jourjikiya, RK | 1 |
| Mukhamedyarov, MA | 1 |
| Kudrin, VS | 1 |
| Klodt, PM | 1 |
| Palotás, A | 1 |
| Luster, M | 1 |
| Karges, W | 1 |
| Zeich, K | 1 |
| Pauls, S | 1 |
| Verburg, FA | 1 |
| Dralle, H | 1 |
| Glatting, G | 1 |
| Buck, AK | 1 |
| Solbach, C | 1 |
| Neumaier, B | 1 |
| Reske, SN | 1 |
| Mottaghy, FM | 1 |
| Schwarz, J | 1 |
| Kuriakose, R | 1 |
| Stoessl, AJ | 2 |
| Goldstein, DS | 1 |
| Holmes, C | 1 |
| Sewell, L | 1 |
| Park, MY | 1 |
| Sharabi, Y | 1 |
| Allen, P | 1 |
| Luigjes, J | 1 |
| Howes, OD | 1 |
| Egerton, A | 1 |
| Hirao, K | 1 |
| Valli, I | 1 |
| Kambeitz, J | 1 |
| Fusar-Poli, P | 1 |
| Broome, M | 1 |
| McGuire, P | 1 |
| Verbeek, HH | 1 |
| Plukker, JT | 1 |
| Koopmans, KP | 1 |
| de Groot, JW | 1 |
| Hofstra, RM | 1 |
| Muller Kobold, AC | 1 |
| van der Horst-Schrivers, AN | 1 |
| Brouwers, AH | 1 |
| Links, TP | 1 |
| Consales, A | 1 |
| Khan, NL | 1 |
| Brooks, DJ | 6 |
| Pavese, N | 3 |
| Sweeney, MG | 1 |
| Wood, NW | 1 |
| Lees, AJ | 1 |
| Marek, K | 1 |
| Jennings, D | 1 |
| Seibyl, J | 1 |
| Rakshi, JS | 2 |
| Uema, T | 1 |
| Ito, K | 1 |
| Morrish, PK | 3 |
| Bailey, DL | 2 |
| Frey, KA | 1 |
| Marek, KL | 1 |
| Oakes, D | 1 |
| Paty, D | 1 |
| Prentice, R | 1 |
| Shults, CW | 1 |
| Heiss, WD | 2 |
| Hilker, R | 2 |
| Grötzsch, H | 1 |
| Schnorf, H | 1 |
| Morris, MA | 1 |
| Moix, I | 1 |
| Horvath, J | 1 |
| Prilipko, O | 1 |
| Burkhard, PR | 1 |
| Sossi, V | 1 |
| de la Fuente-Fernández, R | 1 |
| Schulzer, M | 3 |
| Ruth, TJ | 1 |
| Stoessl, J | 1 |
| Schweitzer, K | 1 |
| Coburger, S | 1 |
| Ghaemi, M | 1 |
| Weisenbach, S | 1 |
| Jacobs, AH | 1 |
| Rudolf, J | 1 |
| Herholz, K | 1 |
| Sato, S | 1 |
| Mizuno, Y | 1 |
| Hattori, N | 1 |
| Borghammer, P | 1 |
| Kumakura, Y | 1 |
| Cumming, P | 1 |
| Zweig, RM | 1 |
| Lilien, DL | 1 |
| Tainter, K | 1 |
| Patterson, J | 1 |
| Brück, A | 2 |
| Aalto, S | 1 |
| Nurmi, E | 3 |
| Vahlberg, T | 1 |
| Bergman, J | 3 |
| Rinne, JO | 3 |
| Tai, YF | 1 |
| Ahsan, RL | 1 |
| de Yébenes, JG | 1 |
| Taïeb, D | 1 |
| Tessonnier, L | 1 |
| Sebag, F | 1 |
| Niccoli-Sire, P | 1 |
| Morange, I | 1 |
| Colavolpe, C | 1 |
| De Micco, C | 1 |
| Barlier, A | 1 |
| Palazzo, FF | 1 |
| Henry, JF | 1 |
| Mundler, O | 1 |
| Vingerhoets, FJ | 2 |
| Snow, BJ | 2 |
| Lee, CS | 1 |
| Mak, E | 1 |
| Calne, DB | 2 |
| Tetrud, JW | 1 |
| Langston, JW | 1 |
| Sawle, GV | 2 |
| Narabayashi, H | 1 |
| Poewe, WH | 1 |
| Wenning, GK | 1 |
| Kaasinen, V | 1 |
| Eskola, O | 1 |
| Solin, O | 2 |
| Ruottinen, HM | 1 |
| Haaparanta, M | 1 |
| Sonninen, P | 1 |
| Jankovic, J | 1 |
| Kapadia, AS | 1 |
| Oechsner, M | 1 |
| Buhmann, C | 1 |
| Strauss, J | 1 |
| Stuerenburg, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials[NCT00354003] | 800 participants (Anticipated) | Observational | 2006-07-31 | Completed | |||
| Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.[NCT00273351] | Phase 2 | 62 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease[NCT00129181] | 30 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's[NCT00096720] | Phase 2 | 112 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Screening Evaluations for Neurologic Syndromes: Olfactory Testing in Relatives of Parkinson's Disease Patients[NCT00096876] | 600 participants (Anticipated) | Observational | 2004-10-31 | Completed | |||
| Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease[NCT00387075] | Phase 2 | 3,000 participants (Anticipated) | Interventional | 2006-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for dihydroxyphenylalanine and Disease Exacerbation
| Article | Year |
|---|---|
18F-FDOPA PET for the diagnosis of parkinsonian syndromes.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Humans; Image Processing, Computer-Assisted; Par | 2014 |
[Nuclear medicine imaging in patients with Parkinson's syndrome: an update].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Energy Metabolism; Fluorodeox | 2010 |
Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
Topics: Animals; Biomarkers; Cerebrovascular Circulation; Corpus Striatum; Dihydroxyphenylalanine; Disease P | 2010 |
Do dopamine agonists or levodopa modify Parkinson's disease progression?
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Dihydroxyphenylalanine; Disease Pro | 2002 |
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
Topics: Animals; Basal Ganglia; Biomarkers; Cocaine; Diagnostic Imaging; Dihydroxyphenylalanine; Disease Pro | 2003 |
The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease.
Topics: Brain; Diagnosis, Differential; Dihydroxyphenylalanine; Disease Progression; Humans; Magnetic Resona | 2004 |
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies.
Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Di | 1995 |
The natural history of Parkinson's disease.
Topics: Cell Count; Dihydroxyphenylalanine; Disabled Persons; Disease Progression; Fluorine Radioisotopes; H | 1998 |
2 trials available for dihydroxyphenylalanine and Disease Exacerbation
| Article | Year |
|---|---|
A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study.
Topics: Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Disease Progression; Fluorine Radioisotopes; Fol | 2002 |
The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study.
Topics: Aged; Aging; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Longitudinal Stud | 1996 |
32 other studies available for dihydroxyphenylalanine and Disease Exacerbation
| Article | Year |
|---|---|
Topics: Brain; Brain Mapping; Dihydroxyphenylalanine; Disease Progression; Dopamine Agents; Female; Fluorode | 2018 |
Covariance statistics and network analysis of brain PET imaging studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Case-Control Studies; Cross-Sectional Studies; Di | 2019 |
(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Topics: Adult; Aged; Brain Neoplasms; Diagnosis, Differential; Dihydroxyphenylalanine; Disease Progression; | 2014 |
Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study.
Topics: Adolescent; Astrocytoma; Biomarkers; Brain; Brain Neoplasms; Child; Dihydroxyphenylalanine; Disease | 2014 |
A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioisotopes; Humans; Image Pr | 2014 |
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chromatography, High Pressure Liquid; C | 2014 |
¹⁸F-fluorodopa positron-emission tomography: an emerging imaging modality for patients with brain metastases.
Topics: Biopsy; Brain Neoplasms; Dihydroxyphenylalanine; Disease Progression; Humans; Neoplasm Recurrence, L | 2014 |
The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma.
Topics: Adult; Aged; Brain Neoplasms; Demography; Dihydroxyphenylalanine; Disease Progression; Female; Fluor | 2015 |
5-S-GAD, a novel radical scavenging compound, prevents lens opacity development.
Topics: alpha-Crystallins; Animals; Biphenyl Compounds; Carnosine; Cataract; Cells, Cultured; Chick Embryo; | 2009 |
Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment.
Topics: Adrenal Glands; Adrenergic beta-Antagonists; Adult; Biomarkers; Chronic Disease; Dihydroxyphenylalan | 2009 |
Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
Topics: Adolescent; Adult; Aged; Calcitonin; Carcinoma, Medullary; Child; Dihydroxyphenylalanine; Disease Pr | 2010 |
Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy.
Topics: Aged; alpha-Synuclein; Autonomic Denervation; Dementia; Dihydroxyphenylalanine; Disease Progression; | 2012 |
Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals.
Topics: Adult; Brain; Brain Mapping; Case-Control Studies; Dihydroxyphenylalanine; Disease Progression; Fema | 2012 |
Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Topics: Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Disease Pr | 2012 |
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
Topics: Adult; Aged; Corpus Striatum; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioiso | 2002 |
Phenotypic heterogeneity of dopa-responsive dystonia in monozygotic twins.
Topics: Adult; Benserazide; Biopterins; Clubfoot; Dihydroxyphenylalanine; Disease Progression; Diseases in T | 2004 |
Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Female; Fluorine Radioisotopes; Humans | 2004 |
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
Topics: Adult; Aged; Cohort Studies; Corpus Striatum; Dihydroxyphenylalanine; Disease Progression; Female; F | 2005 |
Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Aged, 80 and over; Biomarkers; Brain; Creatinine; Deoxygua | 2005 |
Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease.
Topics: Corpus Striatum; Dihydroxyphenylalanine; Disease Progression; Humans; Linear Models; Parkinson Disea | 2005 |
The role of radiotracer imaging in Parkinson disease.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Parkinson Disease; Patient Selection; | 2005 |
Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Topics: Aged; Corpus Striatum; Dihydroxyphenylalanine; Disease Progression; Dominance, Cerebral; Female; Flu | 2006 |
Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study.
Topics: Aged; Amygdala; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Progression; Dopam | 2007 |
The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; Disease Progres | 2008 |
Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Disease Progression; Female; Humans; Male; Middle Aged; Parkins | 1994 |
Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Corpus Striatum; Dihyd | 1994 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex.
Topics: Aged; Dihydroxyphenylalanine; Disease Progression; Dopamine; Female; Functional Laterality; Humans; | 2001 |
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
Topics: Adult; Aged; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Female; Follow-Up Studies | 2001 |
Functional decline in Parkinson disease.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Demogra | 2001 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech | 2002 |